{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T01:10:27Z","timestamp":1725498627176},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1992,11,1]],"date-time":"1992-11-01T00:00:00Z","timestamp":720576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[1992,11]]},"DOI":"10.1007\/bf01789019","type":"journal-article","created":{"date-parts":[[2005,6,20]],"date-time":"2005-06-20T01:50:55Z","timestamp":1119232255000},"page":"401-411","source":"Crossref","is-referenced-by-count":18,"title":["Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-\u03b12a and interleukin-2"],"prefix":"10.1007","volume":"35","author":[{"given":"Shoshana","family":"Morecki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoshana","family":"Revel-Vilk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Nabet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie","family":"Pick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliza","family":"Ackerstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Naparstek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menahem Ben","family":"Shahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimon","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01789019_CR1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood.V71.3.709.709","volume":"71","author":"A Adler","year":"1988","unstructured":"Adler A, Chervenick PA, Whiteside TL, Lotzova E, Herberman RB (1988) Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71: 709","journal-title":"Blood"},{"key":"BF01789019_CR2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/0140-6736(90)93039-R","volume":"335","author":"J Atzpodien","year":"1990","unstructured":"Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H (1990) Home therapy with recombinant interleukin-2 and interferon-a2b in advanced human malignancies. Lancet 335: 1509","journal-title":"Lancet"},{"key":"BF01789019_CR3","first-page":"121","volume":"2","author":"D Blaise","year":"1991","unstructured":"Blaise D, Viens P, Olive D, Stoppa AM, Gabert J, Pourreau CN, Attal M, Gaspard MH, Mannoni P, Jasmin C, Palmer P, Franks C, Michel G, Mawas C, Baume D, Philips T, Maraninchi D. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients (1991) Eur Cytokine Met 2: 121","journal-title":"Eur Cytokine Met"},{"key":"BF01789019_CR4","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.V73.6.1608.1608","volume":"73","author":"MS Borzy","year":"1989","unstructured":"Borzy MS, Ridgway D (1989) Prolonged defects of interleukin-2 production, responsiveness and receptor expression in patients with acute lymphoblastic leukemia. Blood 73: 1608","journal-title":"Blood"},{"issue":"Suppl 97","key":"BF01789019_CR5","first-page":"77","volume":"21","author":"A Boyum","year":"1968","unstructured":"Boyum A (1968) Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest 21 [Suppl 97]: 77","journal-title":"Scand J Clin Lab Invest"},{"key":"BF01789019_CR6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ijc.2910370522","volume":"37","author":"MJ Brund","year":"1986","unstructured":"Brund MJ, Tarnowski D, Davatelis V (1986) Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells. Int J Cancer 37: 787","journal-title":"Int J Cancer"},{"key":"BF01789019_CR7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ijc.2910430410","volume":"43","author":"WC Chang","year":"1989","unstructured":"Chang WC, Fujimiya Y, Casteel N, Pattengale P (1989) Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia: III. Defective interleukin-2 production by T-helper and natural killer cells. Int J Cancer 43: 591","journal-title":"Int J Cancer"},{"key":"BF01789019_CR8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0145-2126(86)90043-3","volume":"10","author":"M Dabholkar","year":"1986","unstructured":"Dabholkar M, Advani S, Tatake R, Gangal S (1986) Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission. Leukemia Res 10: 203","journal-title":"Leukemia Res"},{"key":"BF01789019_CR9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000226698","volume":"46","author":"M Dabholkar","year":"1989","unstructured":"Dabholkar M, Tatake R, Amin K, Advani S, Gangal S (1989) Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin 2 in chronic myeloid leukemia patients in remission. Oncology 46: 123","journal-title":"Oncology"},{"key":"BF01789019_CR10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/JCO.1989.7.4.477","volume":"7","author":"JP Dutcher","year":"1989","unstructured":"Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper M, Parkinson D, Ciobanu N, Fisher RI, Boldt DDH, Doroshow JH, Rayner AA, Hawkins M, Atkins M (1989) A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 7: 477","journal-title":"J Clin Oncol"},{"key":"BF01789019_CR11","first-page":"2020","volume":"47","author":"IJ Fidler","year":"1987","unstructured":"Fidler IJ, Heicappell R, Saiki I, Grutter G, Horsberger MA, Nuesch J (1987) Direct anti-proliferative effects of recombinant human interferon a B\/D hybrids on human tumor cell lines. Cancer Res 47: 2020","journal-title":"Cancer Res"},{"key":"BF01789019_CR12","first-page":"964","volume":"51","author":"R Foa","year":"1991","unstructured":"Foa R, Guarini A, Tos AG, Cardona S, Fierro MT, Meloni G, Tosti S, Mandelli F, Gavosto F (1991) Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation. Cancer Res 51: 964","journal-title":"Cancer Res"},{"key":"BF01789019_CR13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.2910370502","volume":"37","author":"Y Fujimiya","year":"1986","unstructured":"Fujimiya Y, Bakke A, Chang WC, Linker-Isreli M, Udis B, Horowitz D, Pattengale PK (1986) Natural killer-cell immunodeficiency in patients with chronic myelogenous leukemia: I. Analysis of the defect using monoclonal antibodies HNK-1 (Leu-7) and B73.1. Int J Cancer 37: 639","journal-title":"Int J Cancer"},{"key":"BF01789019_CR14","first-page":"2957","volume":"45","author":"G Gastl","year":"1985","unstructured":"Gastl G, Marth C, Leiter E, Gattringer C, Mayer I, Daxenbichler G, Flener R, Huber C (1985) Effects of human recombinant a2 arg-interferon and g-interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res 45: 2957","journal-title":"Cancer Res"},{"key":"BF01789019_CR15","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood.V74.7.2335.2335","volume":"74","author":"DJ Gottlieb","year":"1989","unstructured":"Gottlieb DJ, Prentic HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner MK (1989) Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemoradiotherapy for hematological malignancy. Blood 74: 2335","journal-title":"Blood"},{"key":"BF01789019_CR16","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1084\/jem.155.6.1823","volume":"155","author":"EA Grimm","year":"1982","unstructured":"Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823","journal-title":"J Exp Med"},{"key":"BF01789019_CR17","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1182\/blood.V75.11.2250.2250","volume":"75","author":"M Hauch","year":"1990","unstructured":"Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Malaspinia HC, O'Reilly RJ, Keever CA (1990) Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 75: 2250","journal-title":"Blood"},{"key":"BF01789019_CR18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1126\/science.7025208","volume":"214","author":"RB Herberman","year":"1981","unstructured":"Herberman RB, Ortaldo JR (1981) Natural killer cells: their role in defenses against disease. Science 214: 24","journal-title":"Science"},{"key":"BF01789019_CR19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0167-5699(87)90035-1","volume":"8","author":"RB Herberman","year":"1987","unstructured":"Herberman RB, Hiserodt J, Vujanovic N, Balch C, Lotzova E, Bolhuis R, Golub S, Lanier LL, Phillips JH, Riccardi C, Ritz J, Santoni A, Schmidt RE, Uchida A (1987) Lymphokine-activated killer cell activity. Immunol Today 8: 178","journal-title":"Immunol Today"},{"key":"BF01789019_CR20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood.V67.3.722.722","volume":"67","author":"T Hercend","year":"1986","unstructured":"Hercend T, Takvorian T, Nowill A, Tantravahi R, Moingeon P, Anderson KC, Murray C, Bohuon C, Ythier A, Ritz J (1986) Characterization of natural killer cells with antileukemic activity following allogeneic bone marrow transplantation. Blood 67: 722","journal-title":"Blood"},{"key":"BF01789019_CR21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0167-5699(87)90173-3","volume":"8","author":"P Hersey","year":"1987","unstructured":"Hersey P, Bolhuis R (1987) \u201cNonspecific\u201d MHC-unrestricted killer cells and their receptors. Immunol Today 8: 233","journal-title":"Immunol Today"},{"key":"BF01789019_CR22","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.V74.4.1374.1374","volume":"74","author":"HE Heslop","year":"1989","unstructured":"Heslop HE, Gottlieb DJ, Bianchi AC, Meager A, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK (1989) In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 74: 1374","journal-title":"Blood"},{"key":"BF01789019_CR23","first-page":"5509","volume":"49","author":"CM Higuchi","year":"1989","unstructured":"Higuchi CM, Thompson JA, Cox T, Lindgren CG, Bruckner CD, Fefer A (1989) Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res 49: 5509","journal-title":"Cancer Res"},{"key":"BF01789019_CR24","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.1990.8.10.1657","volume":"8","author":"M Hirsh","year":"1990","unstructured":"Hirsh M, Lipton A, Harvey H, Givant E, Hopper K, Jones G, Zeffren J, Levitt D (1990) Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy. J Clin Oncol 8: 1657","journal-title":"J Clin Oncol"},{"key":"BF01789019_CR25","first-page":"3875","volume":"48","author":"RL Krigel","year":"1988","unstructured":"Krigel RL, Padavic-Shaller KA, Rudolph AR, Litwin S, Konrad M, Bradley EC, Comis RL (1988) A phase I study of recombinant interleukin 2 plus recombinant b-interferon. Cancer Res 48: 3875","journal-title":"Cancer Res"},{"key":"BF01789019_CR26","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.1989.7.11.1726","volume":"7","author":"KH Lee","year":"1989","unstructured":"Lee KH, Talpaz M, Rothberg JM, Murray JL, Papadopoulos N, Plager C, Benjamin R, Levitt D, Gutterman J (1989) Concomitant administration of recombinant human interleukin-2 and recombinant interferon a-2A in cancer patients: a phase I study. J Clin Oncol 7: 1726","journal-title":"J Clin Oncol"},{"key":"BF01789019_CR27","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.4049\/jimmunol.138.8.2718","volume":"138","author":"E Lotzova","year":"1987","unstructured":"Lotzova E, Savary CA, Herberman RB (1987) Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 138: 2718","journal-title":"J Immunol"},{"key":"BF01789019_CR28","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood.V76.10.2037.2037","volume":"76","author":"S Mackinnon","year":"1990","unstructured":"Mackinnon S, Hows JM, Goldman JM (1990) Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood 76: 2037","journal-title":"Blood"},{"key":"BF01789019_CR29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000226741","volume":"46","author":"B Mehta","year":"1989","unstructured":"Mehta B, Advani S, Nadkarni J (1989) Non-Hodgkin's lymphoma: natural cell-mediated cytotoxicity correlated with histological classification and prognosis. Oncology 46: 323","journal-title":"Oncology"},{"key":"BF01789019_CR30","first-page":"269","volume":"7","author":"S Morecki","year":"1991","unstructured":"Morecki S, Nabet C, Ackerstein A, Schlesinger M, Slavin S (1991) The effect of in-vitro T lymphocyte depletion on generation of IL-2 activated cytotoxic cells. Bone Marrow Transplant 7: 269","journal-title":"Bone Marrow Transplant"},{"key":"BF01789019_CR31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1084\/jem.168.1.47","volume":"168","author":"A Nagler","year":"1988","unstructured":"Nagler A, Greenberg PL. Lanier LL, Phillips JH (1988) The effects of recombinant interleukin 2-activated natural killer cells on autologous peripheral blood hematopoietic progenitors. J Exp Med 168: 47","journal-title":"J Exp Med"},{"key":"BF01789019_CR32","unstructured":"Nagler A, Ackerstein A, Naparstek E, Ben-Neriah S, Barak V, Slavin S (1991) Concomitant treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-a2a (in press)"},{"key":"BF01789019_CR33","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood.V68.4.938.938","volume":"68","author":"K Oshimi","year":"1986","unstructured":"Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H (1986) Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 68: 938","journal-title":"Blood"},{"key":"BF01789019_CR34","first-page":"63","volume":"29","author":"G Pawelec","year":"1989","unstructured":"Pawelec G, Schneider E, Ehninger G, Rehbein A, Schmidt H (1989) Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukemia after in vivo treatment with interferon a (Wellferon). Cancer Immunol Immunother 29: 63","journal-title":"Cancer Immunol Immunother"},{"key":"BF01789019_CR35","first-page":"102","volume-title":"Lecture notes on medical statistics","author":"A Petrie","year":"1978","unstructured":"Petrie A (1978) Linear regression and correlation: In: Lecture notes on medical statistics. Blackwell London, p 102"},{"key":"BF01789019_CR36","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1200\/JCO.1987.5.12.1933","volume":"5","author":"JH Phillips","year":"1987","unstructured":"Phillips JH, Genlo BT, Myers WW, Rayner AA, Lanier LL (1987) In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J Clin Oncol 5: 1933","journal-title":"J Clin Oncol"},{"key":"BF01789019_CR37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/02841868909111179","volume":"28","author":"MR Pillai","year":"1989","unstructured":"Pillai MR, Balaram P, Padmanabhan TK, Abraham T, Nair K (1989) Interleukin 2 and alpha interferon induced in vitro modulation of spontaneous cell mediated cytotoxicity in patients with cancer of the uterine cervix undergoing radiotherapy. Acta Oncol 28: 39","journal-title":"Acta Oncol"},{"key":"BF01789019_CR38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198401053100104","volume":"310","author":"JR Quesada","year":"1984","unstructured":"Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (1984) Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310: 15","journal-title":"N Engl J Med"},{"key":"BF01789019_CR39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/BF01742494","volume":"31","author":"N Rajaram","year":"1990","unstructured":"Rajaram N, Tatake RJ, Advani SH, Naik SL, Gangal SG (1990) Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia. Cancer Immunol Immunother 31: 44","journal-title":"Cancer Immunol Immunother"},{"key":"BF01789019_CR40","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.V73.5.1351.1351","volume":"73","author":"JE Rettie","year":"1989","unstructured":"Rettie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, Brenner MK (1989) Endogenously generated activated killer cells circulate after autologous and allogeneic bone marrow transplantation but not after chemotherapy. Blood 73: 1351","journal-title":"Blood"},{"key":"BF01789019_CR41","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood.V76.12.2421.2421","volume":"76","author":"MJ Robertson","year":"1990","unstructured":"Robertson MJ, Ritz J (1990) Biology and clinical relevance of human natural killer cells. Blood 76: 2421","journal-title":"Blood"},{"key":"BF01789019_CR42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0167-5699(88)91261-3","volume":"9","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA (1988) Immunotherapy of cancer using interleukin 2. Immunol Today 9: 58","journal-title":"Immunol Today"},{"key":"BF01789019_CR43","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","volume":"316","author":"SA Rosenberg","year":"1987","unstructured":"Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889","journal-title":"N Engl J Med"},{"key":"BF01789019_CR44","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/00000658-198910000-00008","volume":"210","author":"SA Rosenberg","year":"1989","unstructured":"Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan MW, Siepp CA, White DE (1989) Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474","journal-title":"Ann Surg"},{"key":"BF01789019_CR45","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1200\/JCO.1989.7.12.1863","volume":"7","author":"SA Rosenberg","year":"1989","unstructured":"Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE (1989) Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7: 1863","journal-title":"J Clin Oncol"},{"key":"BF01789019_CR46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-1-4613-1713-5_7","volume":"38","author":"MS Roth","year":"1988","unstructured":"Roth MS, Bunn PA, Foon KA (1988) Interferon therapy for lymphoproliferative disorders. Cancer Treat Res 38: 231","journal-title":"Cancer Treat Res"},{"key":"BF01789019_CR47","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.3131876","volume":"240","author":"KA Smith","year":"1988","unstructured":"Smith KA (1988) Interleukin-2: inception, impact and implication. Science 240: 1169","journal-title":"Science"},{"key":"BF01789019_CR48","unstructured":"Soiffer R, Murray C, Cochran K, Ish C, Wang E, Ritz J (1990) Selective expansion of NK cells in patients given low dose recombinant IL-2 after BMT (abstract). Blood 76 [Suppl 1]: 220a"},{"key":"BF01789019_CR49","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1126\/science.3933111","volume":"230","author":"BJ Sugarman","year":"1985","unstructured":"Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM (1985) Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943","journal-title":"Science"},{"key":"BF01789019_CR50","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V69.5.1280.1280","volume":"69","author":"M Talpaz","year":"1987","unstructured":"Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J (1987) Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69: 1280","journal-title":"Blood"},{"key":"BF01789019_CR51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4613-1493-6_11","volume":"50","author":"WJ Urba","year":"1990","unstructured":"Urba WJ, Steis RG, Longo DL, Kopp WC, Maluish AE, Marcon L, Nelson DL, Stevenson HC, Clark JW (1990) Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res 50: 185","journal-title":"Cancer Res"},{"key":"BF01789019_CR52","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.4049\/jimmunol.142.5.1774","volume":"142","author":"PJ Voogt","year":"1989","unstructured":"Voogt PJ, Falkenburg JHF, Fibbe WE, Veenhof WFJ, Hamilton M, Van Krimpen BA, Bolhuis RLH (1989) Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-\/CD\u2212, T cell receptor+\/CD3+ and T cell receptor ab+\/CD3 lymphocytes. J Immunol 142: 1774","journal-title":"J Immunol"},{"key":"BF01789019_CR53","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1203\/00006450-199012000-00004","volume":"28","author":"A Yabuhara","year":"1990","unstructured":"Yabuhara A, Kawai H (1990) A recycling defect as characteristic of natural killer cells in childhood acute lymphoblastic leukemia. Pediatr Res 28: 572","journal-title":"Pediatr Res"}],"container-title":["Cancer Immunology Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01789019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01789019\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01789019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T01:16:32Z","timestamp":1706318192000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01789019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,11]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1992,11]]}},"alternative-id":["BF01789019"],"URL":"https:\/\/doi.org\/10.1007\/bf01789019","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,11]]}}}